Amarin Corporation (AMRN:NASDAQ) Investor Relations Material

Overview

Amarin Corporation plc, a Dublin-based pharmaceutical company focused on the development and commercialization of treatments for cardiovascular diseases, is expanding its reach worldwide. Its flagship product, VASCEPA, a prescription-only omega-3 fatty acid medication used to reduce triglyceride levels in adult patients with severe hypertriglyceridemia, is currently available in the United States, Canada, various European countries, Lebanon, and the United Arab Emirates. Amarin Corporation plc primarily sells its products to wholesalers and specialty pharmacy providers, and has a partnership with Mochida Pharmaceutical Co., Ltd. to create and sell drug products and indications using the active ingredient in VASCEPA. Originally named Ethical Holdings plc, Amarin Corporation plc has been in operation since 1989 and underwent a name change in 1999.

Frequently Asked Questions

What is Amarin Corporation's ticker?

Amarin Corporation's ticker is AMRN

What exchange is Amarin Corporation traded on?

The company's shares trade on the NASDAQ stock exchange

Where are Amarin Corporation's headquarters?

They are based in Dublin, Ireland

How many employees does Amarin Corporation have?

There are 501-1000 employees working at Amarin Corporation

What is Amarin Corporation's website?

It is amarincorp.com

What type of sector is Amarin Corporation?

Amarin Corporation is in the Healthcare sector

What type of industry is Amarin Corporation?

Amarin Corporation is in the Biotechnology industry

Who are Amarin Corporation's peers and competitors?

The following five companies are Amarin Corporation's industry peers:

- Gritstone bio

- BioMarin Pharmaceutical

- Ceapro Inc.

- Gossamer Bio, Inc.

- Voyager Therapeutics Inc